N4 Pharma Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a N4P.L research report →
Companywww.n4pharma.com
N4 Pharma Plc, a specialist pharmaceutical company, develops novel silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.
- CEO
- David Horn Solomon
- IPO
- 1988
- Employees
- 5
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $3.95M
- P/E
- -3.66
- P/S
- 824.51
- P/B
- 2.28
- EV/EBITDA
- -3.41
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 47.78%
- Op Margin
- -16134.43%
- Net Margin
- -15603.59%
- ROE
- -91.34%
- ROIC
- -60.76%
Growth & Income
- Revenue
- $7.28K · 272.86%
- Net Income
- $-1,059,000 · 16.55%
- EPS
- $-0.00 · 40.38%
- Op Income
- $-1,221,000
- FCF YoY
- 19.65%
Performance & Tape
- 52W High
- $1.00
- 52W Low
- $0.35
- 50D MA
- $0.49
- 200D MA
- $0.51
- Beta
- 0.29
- Avg Volume
- 566.47K
Get TickerSpark's AI analysis on N4P.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our N4P.L Coverage
We haven't published any research on N4P.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate N4P.L Report →